Published Review Current Opinion in Clinical Nutrition and Metabolic Care Why Peptide Users Choose Clean Eatz Exact Macros on Every Label Calories, protein, carbs, and fat printed on every container
Quality of evidence: II-B, Strength of recommendation: 1 Panel level of agreement: In total agreement 96%, in partial agreement 4% The WHC have traditionally been used for diagnosing and grading the severity of clinically overt HE, but they are a subjective tool, with limited interobserver reliability, especially for a grade I classification

Cagrilintide vs semaglutide (Wegovy/Ozempic) Mechanism: Cagrilintide: Amylin receptor agonist Semaglutide: GLP-1 receptor agonist Different pathways Weight loss: Cagrilintide alone: 10-12% Semaglutide alone: 10-15% Similar efficacy monotherapy Gastric emptying: Cagrilintide: Very strong delay Semaglutide: Moderate delay Cagrilintide more powerful Side effects: Cagrilintide: More GI effects (stronger gastric slowing) Semaglutide: Moderate GI effects Cagrilintide harder to tolerate for some Availability: Cagrilintide: Investigational (not approved) Semaglutide: FDA approved, widely available Semaglutide easier to obtain currently Combination potential: Synergistic together (CagriSema) 15-25% weight loss combined Best of both mechanisms Verdict: Similar monotherapy efficacy, but combine for maximum results
2022;42:BSR20212808
HernndezMendoza, A
CJC-1295 for growth hormone support CJC-1295 is a growth hormone-releasing hormone (GHRH) analogue that can stimulate the release of growth hormone from the pituitary